Ibrance (palbociclib) — Medica
Breast cancer in a woman
Initial criteria
- age ≥ 18 years
- recurrent or metastatic disease
- hormone receptor positive (HR+) [estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)] disease
- human epidermal growth factor receptor 2 (HER2)-negative breast cancer
- EITHER: postmenopausal OR (pre/perimenopausal AND (receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist OR has had surgical bilateral oophorectomy or ovarian irradiation))
- Ibrance will be used in combination with anastrozole, exemestane, or letrozole OR used in combination with fulvestrant
Approval duration
1 year